BY vs SRPT · P/E 9.9, rev $286.0M vs rev $1.13B
Byline Bancorp Inc (BY) versus Sarepta Therapeutics Inc (SRPT) — a side-by-side from cached financials, not a winner call.
Byline Bancorp Inc (BY) is a banks - regional company listed on US.
Sarepta Therapeutics Inc (SRPT) is a biotechnology company listed on US.
Latest reported BY revenue for 2026-06-30 was $286.0M. Net income was $77.8M. BY currently screens at market cap $1.22B and trailing P/E 9.9.
Latest reported SRPT revenue for 2026-06-30 was $1.13B. Net income was $326.1M. Revenue was up 54.9% from 2026-03-31 to 2026-06-30. SRPT currently screens at market cap $2.34B.
BY currently screens at market cap $1.22B and trailing P/E 9.9. SRPT currently screens at market cap $2.34B.
Not investment advice. Open the BY and SRPT stock pages for the full models.
Not investment advice.